AVIR - Atea Pharmaceuticals  - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

AVIR is currently covered by 2 analysts with an average price target of $6.77. This is a potential upside of $3.81 (128.72%) from yesterday's end of day stock price of $2.96.

Atea Pharmaceuticals 's activity chart (see below) currently has 24 price targets and 17 ratings on display. The stock rating distribution of AVIR is 66.67% SELL and 33.33% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 65% with an average time for these price targets to be met of 49 days.

Highest price target for AVIR is $6, Lowest price target is $6, average price target is $6.

Most recent stock forecast was given by MATTHEW HARRISON from MORGAN STANLEY on 11-Apr-2025. First documented stock forecast 24-Nov-2020.

Best performing analysts who are covering AVIR - Atea Pharmaceuticals :

Eric Joseph Matthew Harrison

Currently out of the existing stock ratings of AVIR, 2 are a SELL (66.67%), 1 are a HOLD (33.33%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$6

$3.11 (107.61%)

$6.88

17 days ago
(11-Apr-2025)

7/10 (70%)

$3.29 (121.40%)

43

Sell

$8

1 years 8 months 18 days ago
(10-Aug-2023)

3/5 (60%)

$4.32 (117.39%)

55

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is AVIR (Atea Pharmaceuticals ) average time for price targets to be met?

On average it took 49 days on average for the stock forecasts to be realized with a an average price target met ratio 65

Which analyst has the current highest performing score on AVIR (Atea Pharmaceuticals ) with a proven track record?

ERIC JOSEPH

Which analyst has the current lower performing score on AVIR (Atea Pharmaceuticals ) with a proven track record?

MATTHEW HARRISON

Which analyst has the most public recommendations on AVIR (Atea Pharmaceuticals )?

Eric Joseph works at JPMORGAN and has 4 price targets and 2 ratings on AVIR

Which analyst is the currently most bullish on AVIR (Atea Pharmaceuticals )?

Matthew Harrison with highest potential upside - $3.11

Which analyst is the currently most reserved on AVIR (Atea Pharmaceuticals )?

Eric Joseph with lowest potential downside - -$0

Atea Pharmaceuticals  in the News

Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect HCV Infection Remains a Significant Global Health Burden, with Approximately 50 Million People Infected, Including up to 4 Million in US New Next-Generation HCV Therapies are Needed to Improve Patient Outcomes BOSTON, April 09, 2025 (GLOBE NEWSWIRE) —...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?